Atyr Pharma Inc. (NASDAQ:LIFE) shares were down 1.4% on Tuesday . The company traded as low as $3.39 and last traded at $3.61, with a volume of 116,867 shares changing hands. The stock had previously closed at $3.66.

A number of research analysts recently weighed in on LIFE shares. Zacks Investment Research upgraded Atyr Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. BMO Capital Markets reiterated a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. JPMorgan Chase & Co. reduced their target price on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, Citigroup Inc. lifted their target price on Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $6.00.

The company’s market cap is $83.38 million. The company has a 50-day moving average price of $2.97 and a 200 day moving average price of $3.71.

Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. On average, equities analysts expect that Atyr Pharma Inc. will post ($2.63) EPS for the current year.

A hedge fund recently raised its stake in Atyr Pharma stock. RS Investment Management Co. LLC increased its position in Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned approximately 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.